Live Biotherapeutic Product (LBP) Market Vendor and Technology Assessment Report 2024-2031

Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Live Biotherapeutic Product (LBP) Market (By Type of Product(Probiotic drugs, Other drugs), By Type of Molecule(Small molecules, Biologics), By Target disease indication(Graft Versus Host Disease, Necrotizing Enterocolitis, Primary Hyperoxaluria, Recurrent C. difficile Infection, Others), By Therapeutic area (Digestive and Gastrointestinal Disorders, Infectious Diseases, Rare Disorders, Others), By route of administration(Oral therapeutics, Rectal therapeutics))- Market Outlook and Industry Analysis 2030"

The company's most recent study indicates that the global market for live biotherapeutic products (LBPs) is valued at US$ 355.9 million in 2021 and is expected to grow at a promising compound annual growth rate (CAGR) of 25.2% between 2022 and 2030, reaching US $ 2608.0 million.

Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/1152

A well-known new medication called "live biotherapeutics" uses living things like bacteria. These live microbiome medications can potentially change how many diseases are treated while also preventing, treating, and curing human illnesses. There is no vaccination category in these treatments. Numerous substances that significantly impact human health and well-being are produced and consumed by these bacteria. Crucially, by influencing the local ecology, other microorganisms, and their interactions with the host, LBPs will also have a biological effect. Reintroducing beneficial bacteria may serve as therapeutically helpful treatments to restore and preserve a healthy microbiome. Local ecology, other microorganisms, and their interactions with the host, LBPs will also have a biological effect.

Expanding R&D activities and a growing pipeline of microbiome-targeting treatments, which are expected to cure a wide range of critical diseases, are expected to propel market expansion throughout the forecast period. The market is expanding due to growing technological advancements and innovation in creating novel medications and clinical trials for treating illnesses. Significant growth potential is expected during the forecast period as a result of increasing government financing and a larger R&D budget for drug development. In the past two years, more than 640 patents pertaining to microbiome therapies have been approved.

Insufficient expertise, a lack of specialized infrastructure that requires excessive capital investment, and the need for high capital expenditure are some of the challenges associated with ensuring compliance with good manufacturing practices (GMP), associated safety issues with LBPs, and capacity. It is anticipated that these constraints will limit market expansion. However, North America is expected to increase during the forecast period (2022-2030) due to the substantial burden of bacterial infection diseases and the growing demand for new novel drugs. Businesses receive significant funding for research and product development on Live Biotherapeutic ingredients.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

The key players involved in live biotherapeutic products industry are Seres Therapeutics, Inc., Microbiotica, Enterome, Destiny Pharma plc, Taisho Pharmaceutical Holdings, AOBiome Therapeutics, Inc., Finch Therapeutics Group, Inc, Ferring Pharmaceuticals, Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals), MaaT Pharma, Vedanta Biosciences Inc., OxThera AB, Pendulum Therapeutics, Caelus Health, Quorum Innovations, Sanofi S.A, DermBiont, Inc., EnteroBiotix Ltd, YSOPIA Bioscience, Winclove Probiotics, TargEDys, Evelo Biosciences, Inc., BiomX, Biomica Ltd., Scioto Biosciences, Inc., Lactobio A/S, Takeda Pharmaceutical Co. Ltd., Second Genome Therapeutics, Johnson and Johnson Inc., Kaleido Biosciences Inc., OptiBiotix Health Plc, PureTech Health Plc, Immuron Limited, Naked Biome, Synthetic Biologics, ExeGi Pharma, Nexbiome, Mybiotics Pharma LTD, 4D pharma plc, Axial Therapeutics, Inc., BrickBuilt Therapeutics, Siolta Therapeutics, Stellate Therapeutics, Sciotio Biosciences Inc, Rise Therapeutics, EverImmune S.A. and others.

Key developments in the market:
• In Mar 2022, Microbiotica has accomplished a £50 million ($67 million) Series B financing round, the largest microbiome-related financing round in Europe to date. The assets will also be used to advance Microbiotica's two lead oral Live Bacterial Therapeutics (LBTs), MB097 and MB310, to Phase 1b clinical trials, as well as LBTs in new disease areas.
• In Nov 2021, Together by collaboration, Bacthera and Seres Therapeutics will commercially manufacture SER-109, a possible cure for recurrent C. difficile infection. According to the terms of the contract, Bacthera will build a special facility for commercial production in its new facility Microbiome Center of Excellence on Lonza's Ibex campus in Visp, Switzerland that is devoted to the production of LBPs.
• In Aug 2021, Finch Therapeutics announced that the development of the FIN-524 Ulcerative Colitis Program will be accelerated its strategic partner Takeda. Prior to the anticipated start of clinical-stage development, Takeda will take over primary development responsibility for the programme, which is now known as TAK-524. With the change, Takeda will be able to use its knowledge of inflammatory bowel disease (IBD) for the duration of the clinical development of FIN-524/TAK-524.
• In Nov 2020, ExeGi Pharma declares EXE-346 Live Biotherapeutic an FDA orphan drug. Drugs and biological products designed to treat diseases that affect fewer than 200,000 patients in the US are given some advantages thanks to this designation. An LBP called EXE-346 has a fixed-proportion of 8 live probiotic bacterial strains that are meant to be taken orally.

Unlock Your GTM Strategy: www.insightaceanalytic.com/customisation/1152

Market Segmentation
Live Biotherapeutic Product (LBP) Market, by Type Of Product, 2022-2030 (Value US$ Mn)
• Probiotic Drugs
• Other Drugs

Live Biotherapeutic Product (LBP) Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
• Small Molecules
• Biologics

Live Biotherapeutic Product (LBP) Market, by Target disease indication, 2022-2030 (Value US$ Mn)
• Graft Versus Host Disease
• Necrotizing Enterocolitis
• Primary Hyperoxaluria,
• Recurrent C. difficile Infection
• Others
Live Biotherapeutic Product (LBP) Market, by Therapeutic area, 2022-2030 (Value US$ Mn)
• Digestive and Gastrointestinal Disorders
• Infectious Diseases
• Rare Disorders
• Others

Live Biotherapeutic Product (LBP) Market, by Route of administration, 2022-2030 (Value US$ Mn)
• Oral Therapeutics
• Rectal Therapeutics

Live Biotherapeutic Product (LBP) Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1152

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.